
    
      Eligible patients will be randomly assigned to parallel dosing groups of CF101 2 mg or
      matching placebo tablets twice daily (BID) in a 1:1 ratio for the 16-week controlled
      treatment period. Approximately 94 patients will be assigned to each group.

      Medication will be taken orally BID for 16 weeks in a double-blinded fashion. At the end of
      16 weeks, all patients assigned to CF101 will continue CF101, while patients originally
      assigned to placebo will be reassigned to CF101.

      Assessment of peripheral blood mononuclear cell (PBMC) adenosine A3 receptor (A3AR)
      expression at baseline and during treatment with CF101 in selected sites.
    
  